8-K: Arcutis Announces Strong Q4 and Full Year 2024 Results Driven by ZORYVE Growth

Arcutis Biotherapeutics reports a significant increase in revenue for Q4 and full year 2024, driven by strong demand for ZORYVE and strategic commercial initiatives.

Summary

• Arcutis Biotherapeutics announced its Q4 and full year 2024 financial results, showcasing substantial revenue growth.
• Q4 2024 net product revenue for ZORYVE was $69.4 million, a 413% increase compared to Q4 2023 and a 55% increase compared to Q3 2024, including a $4.1 million non-recurring adjustment.
• Full year 2024 net product revenue for ZORYVE reached $166.5 million, a 471% increase over the prior year.
• The company submitted a supplemental New Drug Application (sNDA) to the FDA for ZORYVE cream 0.05% for treating atopic dermatitis in children aged 2 to 5.
• Arcutis made a $100 million partial prepayment on its outstanding debt.
• Total revenues for Q4 2024 were $71.4 million, compared to $13.5 million in Q4 2023.
• Total revenues for the full year 2024 were $196.5 million, compared to $59.6 million in 2023.
• The net loss for Q4 2024 was $10.8 million, or $0.09 per share, compared to a net loss of $66.3 million, or $0.72 per share, in Q4 2023.
• The net loss for the full year 2024 was $140.0 million, or $1.16 per share, compared to a net loss of $262.1 million, or $3.78 per share, in 2023.
• As of December 31, 2024, Arcutis had $228.6 million in cash, cash equivalents, restricted cash, and marketable securities.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, reduced net losses, and successful product launches. The company is making strategic moves to expand market access and develop its pipeline, indicating a healthy trajectory.

Positives

• Significant revenue growth driven by ZORYVE product sales.
• Successful commercial launches for new ZORYVE indications.
• Improved gross-to-net (GTN) sales deductions.
• Expanded Medicaid coverage for ZORYVE cream to additional states.
• Strong demand for ZORYVE foam in seborrheic dermatitis.
• FDA acceptance of sNDA for ZORYVE foam for scalp and body psoriasis with a PDUFA action date set for May 22, 2025.
• Reduced net loss compared to the previous year.
• Partial prepayment of debt, improving financial flexibility.

Negatives

• Increased selling, general, and administrative (SG&A) expenses due to higher sales force headcount and marketing expenses.
• The company still reported a net loss for both the quarter and the full year, although significantly reduced from the previous year.
• Cost of sales increased compared to the corresponding periods in 2023.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those related to clinical development, regulatory approval, commercialization, and intellectual property.
• Uncertainty of future commercial sales and related items can impact net sales.
• The company's ability to defend its intellectual property is a risk factor.

Future Outlook

Arcutis anticipates continued improvement in coverage for ZORYVE cream 0.15% during 2025 and aims to obtain Medicaid coverage in additional states, as well as some Medicare coverage, during 2025. The company expects data from the Phase 1b study evaluating ARQ-255 for alopecia areata in H1 2025 and is working towards submitting an Investigational New Drug application in 2025 for ARQ-234.

Management Comments

• 'Our success in 2024 was driven by growing ZORYVE momentum, including commercial launches for two new indications for ZORYVE, and our pricing and access strategy that led to strong commercial and government reimbursement,' said Frank Watanabe, president and chief executive officer.
• Frank Watanabe stated that ZORYVE is the number one prescribed branded non-steroidal topical, due to its compelling value proposition of effectively and safely relieving multiple inflammatory skin conditions anywhere on the body for any duration.
• Frank Watanabe believes the company is well positioned to realize its mission of addressing unmet needs and the lack of innovation in medical dermatology.

Industry Context

Arcutis is operating in the competitive immuno-dermatology market, focusing on innovative treatments for inflammatory skin conditions. The company's success with ZORYVE positions it as a key player in the non-steroidal topical treatment space, challenging established therapies and addressing unmet needs in conditions like psoriasis, atopic dermatitis, and seborrheic dermatitis.

Comparison to Industry Standards

• Arcutis's ZORYVE competes with other topical treatments for psoriasis and atopic dermatitis, including corticosteroids and other non-steroidal options like those from companies such as Incyte (Opzelura) and LEO Pharma (Enstilar).
• The 471% increase in ZORYVE revenue indicates strong market adoption, potentially exceeding the growth rates of some competitors in the topical dermatology space.
• The focus on Medicaid and Medicare coverage expansion aligns with industry efforts to improve patient access to innovative therapies, similar to strategies employed by companies like Amgen and AbbVie for their dermatology products.
• The submission of sNDAs for new indications reflects a lifecycle management strategy common among pharmaceutical companies, such as Novartis and Sanofi, to maximize the value of their approved products.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and reduced net losses.
• Employees may benefit from the company's growth and expansion.
• Patients will have increased access to innovative treatments for dermatological conditions.
• Payers will need to consider the value proposition of ZORYVE and other Arcutis products in their reimbursement decisions.

Next Steps

• The company anticipates a target action date in Q4 2025 for the sNDA for ZORYVE cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5.
• The company awaits the PDUFA action date of May 22, 2025, for ZORYVE foam for scalp and body psoriasis.
• The company expects data from the Phase 1b study evaluating ARQ-255 for alopecia areata in H1 2025.
• The company is working towards submitting an Investigational New Drug application in 2025 for ARQ-234.

Key Dates